Short Course

Dinner Short Course: Funding Opportunities for Antibacterial Research* 

5:30-8:30 pm, November 17 

Melissa Stundick, Ph.D., Chief, Anti-infectives Program, BARDA
Rosemarie Aurigemma, Ph.D., Chief, Drug Development Section, DMID, NIAID

The course will cover:

  • From basic research to the clinic – how do we support the discovery & development of new agents?
  • Grants, contracts and biodefense partnerships
  • Preclinical, nonclinical, and clinical product development services

About Instructors:  

melissa stundikMelissa Stundick, Ph.D., is the Anti-infectives Program Chief within the Biomedical Advanced Research and Development Authority (BARDA) at the Department of Health and Human Services (DHHS). She oversees a portfolio of contracts which support the procurement or advanced research and development of the following therapeutics: novel antibacterials, smallpox antivirals, antitoxins, and ebola therapeutics. Prior to joining BARDA in 2011, Dr. Stundick provided scientific and program management support as a Contractor to a number of Government and private entities, including the Department of Defense, Department of Homeland Security, National Center for Medical Intelligence (NMCI), and the Bill and Melinda Gates Foundation.  She received her PhD from the Johns Hopkins School of Medicine and her B.S. in Chemistry from Bates College. She also holds a Certificate of Intelligence Analysis from the University of Maryland.

Aurigemma RosemarieRose Aurigemma, Ph.D., is Chief of the Drug Development Section in the Office of Biodefense Research Resources and Translational Research at NIAID, NIH, where she directs the advancement of new therapies for infectious diseases important to public health such as influenza, antibiotic resistant infections, and dengue fever, as well as for infectious bioterrorism agents, such as anthrax. The work supported under her group has resulted in advancement of valuable new products for treating anthrax, pandemic flu, botulism and drug resistant bacterial infections. Dr. Aurigemma collaborates with other federal agencies within the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE) including the CDC, FDA, DoD, BARDA and DHS. In this role, she contributes to the establishment of policies and practices for meeting the nation’s emergency medical countermeasure needs. In 2014, Dr. Aurigemma’s group was responsible for gathering pivotal study data to advance promising drugs to treat Ebola Virus Disease. Dr. Aurigemma has also collaborated with federal colleagues on crafting and implementing the Combating Antibiotic Resistant Bacteria (CARB) initiative.  Prior to joining NIH in 2009, Dr. Aurigemma managed oncology product development at the National Cancer Institute, NIH, where she ushered a number of novel cancer therapies to clinical trials. Her earlier experience was in drug discovery and development and clinical development in the biotechnology industry. Dr. Aurigemma holds a Ph.D. in Microbiology from Colorado State University and a B.S. in Biology from Cornell University.

*Separate Registration Required 

By Series:
By Region:

& Course Catalog

CHI Catalog 

Short Course DVDs